Cannabinoid receptor full agonists may perhaps present critical potential risks for the person when used to surplus. Several physical and psychological adverse results have documented from JWH-018 use.(two) For that applications of monitoring within the framework from the EU Early Warning Process, the term ‘artificial cannabinoids’ is employed